🚀 VC round data is live in beta, check it out!
Travere Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Travere Therapeutics and similar public comparables like SK Bioscience, Buchang Pharma, WAVE Life Sciences, Apellis Pharmaceuticals and more.
Travere Therapeutics Overview
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Founded
2011
HQ
Employees
497
Website
Sectors
Financials (LTM)
EV
$3B
Travere Therapeutics Financials
Travere Therapeutics reported last 12-month revenue of $535M and EBITDA of $49M.
In the same LTM period, Travere Therapeutics generated $520M in gross profit, $49M in EBITDA, and had net loss of ($7M).
Revenue (LTM)
Travere Therapeutics P&L
In the most recent fiscal year, Travere Therapeutics reported revenue of $491M and EBITDA of $28M.
Travere Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $535M | XXX | $491M | XXX | XXX | XXX |
| Gross Profit | $520M | XXX | $480M | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | $49M | XXX | $28M | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 6% | XXX | XXX | XXX |
| EBIT Margin | (6%) | XXX | (13%) | XXX | XXX | XXX |
| Net Profit | ($7M) | XXX | ($26M) | XXX | XXX | XXX |
| Net Margin | (1%) | XXX | (5%) | XXX | XXX | XXX |
| Net Debt | — | — | $219M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Travere Therapeutics Stock Performance
Travere Therapeutics has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
Travere Therapeutics' stock price is $28.18.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $-0.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTravere Therapeutics Valuation Multiples
Travere Therapeutics trades at 4.9x EV/Revenue multiple, and 53.0x EV/EBITDA.
EV / Revenue (LTM)
Travere Therapeutics Financial Valuation Multiples
As of March 21, 2026, Travere Therapeutics has market cap of $3B and EV of $3B.
Equity research analysts estimate Travere Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Travere Therapeutics has a P/E ratio of (350.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 4.9x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | 53.0x | XXX | 93.6x | XXX | XXX | XXX |
| EV/EBIT | (78.3x) | XXX | (41.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | 5.4x | XXX | XXX | XXX |
| P/E | (350.0x) | XXX | (101.8x) | XXX | XXX | XXX |
| EV/FCF | 12.1x | XXX | 11.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Travere Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Travere Therapeutics Margins & Growth Rates
Travere Therapeutics' revenue in the last 12 month grew by 40%.
Travere Therapeutics' revenue per employee in the last FY averaged $1.1M.
Travere Therapeutics' rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Travere Therapeutics' rule of X is 108% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Travere Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | 42% | XXX | XXX | XXX |
| EBITDA Margin | 9% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Growth | 281% | XXX | 354% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 108% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 67% | XXX | 69% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 38% | XXX | 42% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 111% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Travere Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SK Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Buchang Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| WAVE Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Apellis Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hisamitsu Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Travere Therapeutics M&A Activity
Travere Therapeutics acquired XXX companies to date.
Last acquisition by Travere Therapeutics was on XXXXXXXX, XXXXX. Travere Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Travere Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTravere Therapeutics Investment Activity
Travere Therapeutics invested in XXX companies to date.
Travere Therapeutics made its latest investment on XXXXXXXX, XXXXX. Travere Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Travere Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Travere Therapeutics
| When was Travere Therapeutics founded? | Travere Therapeutics was founded in 2011. |
| Where is Travere Therapeutics headquartered? | Travere Therapeutics is headquartered in United States. |
| How many employees does Travere Therapeutics have? | As of today, Travere Therapeutics has over 497 employees. |
| Who is the CEO of Travere Therapeutics? | Travere Therapeutics' CEO is Eric M. Dube. |
| Is Travere Therapeutics publicly listed? | Yes, Travere Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Travere Therapeutics? | Travere Therapeutics trades under TVTX ticker. |
| When did Travere Therapeutics go public? | Travere Therapeutics went public in 2003. |
| Who are competitors of Travere Therapeutics? | Travere Therapeutics main competitors are SK Bioscience, Buchang Pharma, WAVE Life Sciences, Apellis Pharmaceuticals. |
| What is the current market cap of Travere Therapeutics? | Travere Therapeutics' current market cap is $3B. |
| What is the current revenue of Travere Therapeutics? | Travere Therapeutics' last 12 months revenue is $535M. |
| What is the current revenue growth of Travere Therapeutics? | Travere Therapeutics revenue growth (NTM/LTM) is 40%. |
| What is the current EV/Revenue multiple of Travere Therapeutics? | Current revenue multiple of Travere Therapeutics is 4.9x. |
| Is Travere Therapeutics profitable? | Yes, Travere Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Travere Therapeutics? | Travere Therapeutics' last 12 months EBITDA is $49M. |
| What is Travere Therapeutics' EBITDA margin? | Travere Therapeutics' last 12 months EBITDA margin is 9%. |
| What is the current EV/EBITDA multiple of Travere Therapeutics? | Current EBITDA multiple of Travere Therapeutics is 53.0x. |
| What is the current FCF of Travere Therapeutics? | Travere Therapeutics' last 12 months FCF is $216M. |
| What is Travere Therapeutics' FCF margin? | Travere Therapeutics' last 12 months FCF margin is 40%. |
| What is the current EV/FCF multiple of Travere Therapeutics? | Current FCF multiple of Travere Therapeutics is 12.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.